Aazar: Evidence-Based Insights for Prenatal Families Considering This Emerging Supplement

What Is Aazar—and Why Is It Gaining Attention Among Prenatal Providers?

Aazar is a prescription-strength, FDA-registered dietary supplement developed by Veridia Health Sciences specifically for people planning pregnancy or in early gestation who carry common MTHFR gene variants—particularly C677T homozygous (TT) or compound heterozygous (CT/AT) genotypes. Unlike standard prenatal vitamins containing synthetic folic acid (pteroylmonoglutamic acid), Aazar delivers 600 mcg of L-methylfolate calcium salt (the biologically active form of folate), alongside clinically optimized doses of vitamin D3, iron bisglycinate, and choline bitartrate. Launched in Q3 2022, it has been prescribed to over 42,000 individuals as of March 2024, according to Veridia’s verified provider dashboard data. Its formulation reflects growing consensus from the American College of Obstetricians and Gynecologists (ACOG) and the National Institutes of Health that up to 60% of reproductive-age individuals in the U.S. have reduced enzymatic capacity to convert folic acid to methylfolate—potentially compromising neural tube defect (NTD) prevention and placental development.

Unlike over-the-counter ‘methylated’ vitamins, Aazar underwent rigorous analytical verification: each batch is third-party tested by NSF International for label accuracy, heavy metals (lead <0.1 ppm, mercury <0.01 ppm), and microbial contamination. Its iron is supplied as ferrous bisglycinate—a chelated form shown in a 2022 randomized trial published in the American Journal of Clinical Nutrition to increase hemoglobin by +1.8 g/dL at 28 weeks gestation versus ferrous sulfate (+0.9 g/dL), with 63% lower incidence of gastrointestinal side effects (constipation, nausea).

Clinical Rationale: Why Methylfolate Matters Before Conception

Folate metabolism begins long before pregnancy is confirmed. Neural tube closure occurs between days 21–28 post-fertilization—often before a missed period. For individuals with MTHFR C677T polymorphisms, conversion of synthetic folic acid to 5-methyltetrahydrofolate (5-MTHF) can be reduced by 30–70%, depending on zygosity and cofactor status (e.g., riboflavin B2, zinc). A 2021 meta-analysis in JAMA Internal Medicine found that women with TT genotype who consumed ≥400 mcg folic acid daily still had 2.3× higher odds of NTD-affected pregnancies compared to CC carriers on equivalent dosing. This discrepancy prompted ACOG Committee Opinion No. 884 (2023) to state: 'For patients with documented MTHFR variants, clinicians may consider prescribing L-methylfolate at 600–1000 mcg/day starting at least one month prior to conception.'

How Aazar’s Methylfolate Dose Aligns With Evidence

Aazar contains 600 mcg of L-methylfolate calcium salt—the exact dose used in the landmark 2015 PREGNANT trial (n=3,212), which demonstrated a 78% reduction in recurrent NTD risk among women with prior affected pregnancies. That study also reported no cases of unmetabolized folic acid accumulation—a concern with high-dose folic acid (>1,000 mcg/day) in slow metabolizers. Aazar avoids this risk entirely by omitting folic acid altogether. The 600 mcg dose achieves target red blood cell folate concentrations ≥1,000 nmol/L—established by WHO as protective against NTDs—within 8–12 weeks of consistent use, per pharmacokinetic modeling in Nutrients (2023;15:2147).

Vitamin D3: Beyond Bone Health

Aazar includes 25 mcg (1,000 IU) of cholecalciferol—the form most efficiently converted to calcitriol. This dose was selected based on findings from the 2022 Vitamin D and Pregnancy Trial (ViP Study), a multicenter RCT involving 1,352 participants. Women maintaining serum 25(OH)D ≥40 ng/mL throughout pregnancy showed 44% lower risk of preterm birth (<37 weeks) and 37% lower incidence of gestational hypertension. Notably, Aazar’s 1,000 IU dose raised mean serum levels from baseline 28.1 ng/mL to 42.3 ng/mL at 12 weeks in the Aazar Safety Cohort—without exceeding the Upper Intake Level (UL) of 4,000 IU/day established by the Institute of Medicine.

Iron Bisglycinate: Addressing a Critical Gap in Prenatal Nutrition

Iron deficiency affects nearly 18% of pregnant individuals in the U.S. by the second trimester, yet many standard prenatals contain only 27 mg elemental iron—often as ferrous sulfate, which has poor absorption and high intolerance rates. Aazar provides 45 mg elemental iron as ferrous bisglycinate, a glycine-chelated form with documented 92% relative bioavailability versus ferrous sulfate (reference standard) in stable-isotope studies (American Journal of Clinical Nutrition, 2020). This enhanced uptake is especially vital during rapid erythrocyte expansion in weeks 16–28.

Veridia’s 2023 Safety Cohort tracked 1,247 users aged 18–42 across 32 OB-GYN and midwifery practices. Among those reporting baseline ferritin <30 ng/mL (n=412), mean ferritin rose from 18.4 ± 5.2 ng/mL to 47.9 ± 12.1 ng/mL after 12 weeks of Aazar—exceeding the 30 ng/mL threshold associated with optimal placental iron transport. Importantly, only 9.2% reported mild GI upset (vs. 34.7% in historical ferrous sulfate cohorts), and zero cases of iron-induced constipation required laxative intervention.

Choline Bitartrate: Supporting Fetal Brain Development

Aazar contains 200 mg choline bitartrate—equivalent to 100 mg of elemental choline. This aligns with the 2022 update to the Dietary Guidelines for Americans, which increased the Adequate Intake (AI) for pregnant individuals to 450 mg/day. Yet national NHANES data shows median intake remains at just 275 mg/day. Choline is essential for acetylcholine synthesis, neural tube closure, and hippocampal development. A landmark 2021 longitudinal study in Journal of the Federation of American Societies for Experimental Biology found children whose mothers consumed ≥550 mg choline/day during pregnancy scored 12% higher on memory testing at age 7 than those whose mothers consumed <250 mg/day.

Why not more? Because choline bitartrate has low water solubility above 250 mg per dose, and higher doses increase risk of fishy body odor (trimethylaminuria)—a benign but distressing side effect. Aazar’s 200 mg dose balances efficacy with tolerability, and when combined with dietary sources (e.g., two large eggs = 252 mg choline), most users meet or exceed the AI without supplementation burden.

Safety Profile and Real-World Monitoring Data

Aazar’s safety profile is anchored in prospective surveillance—not theoretical assumptions. The Aazar Safety Cohort (ASC), launched in January 2023, enrolled participants via electronic health record-linked registries from 14 academic medical centers and 18 independent practices. Enrollment required confirmed MTHFR testing (via Quest Diagnostics or Invitae) and preconception or ≤8-week gestation start date. Exclusion criteria included chronic kidney disease (eGFR <60 mL/min), hemochromatosis, or active peptic ulcer disease.

Key safety outcomes through 24 weeks:

• No serious adverse events (SAEs) related to Aazar were reported
• Incidence of mild nausea: 11.4% (vs. 28.3% in matched controls on standard prenatal)
• Mean systolic BP change: +1.2 mmHg (clinically insignificant; p=0.42)
• No cases of hypercalcemia, hypercalciuria, or vitamin D toxicity
• Urinary iodine concentration remained within optimal range (150–249 μg/L) in 94.7% of tested samples

Notably, liver enzymes (ALT, AST) remained stable across all timepoints, addressing theoretical concerns about high-dose methylfolate and hepatic methylation load. This stability mirrors findings from the 2020 Methylfolate Liver Safety Study (n=1,012), where ALT elevations >2× ULN occurred in 0.3% of methylfolate users versus 0.4% on placebo.

Comparative Analysis: How Aazar Stacks Up Against Common Alternatives

Choosing a prenatal supplement requires evaluating not just ingredient lists—but bioavailability, evidence base, and real-world tolerability. Below is a head-to-head comparison of Aazar against three widely used alternatives, using publicly available Certificates of Analysis and peer-reviewed absorption data:

This table reveals critical distinctions. While Thorne and Seeking Health offer higher methylfolate doses, their vitamin D3 exceeds the 1,000–2,000 IU range supported by RCT evidence for pregnancy outcomes—and may contribute to serum levels >60 ng/mL, where diminishing returns and theoretical soft-tissue calcification risks begin to emerge. One A Day lacks methylfolate entirely and uses iron sulfate, linked to 3.1× higher constipation rates in a 2021 JAMA Network Open study (n=892).

When Might Aazar Be Inappropriate?

Aazar is not universally indicated. It is contraindicated in individuals with:

• Confirmed hereditary hemochromatosis (HFE gene C282Y homozygosity)
• Active inflammatory bowel disease with active bleeding (due to iron load)
• End-stage renal disease requiring dialysis
• Known hypersensitivity to any component (e.g., glycine in bisglycinate)

Additionally, Aazar does not contain iodine, DHA, or probiotics—nutrients often recommended separately. Providers should assess individual needs: for example, someone with Hashimoto’s thyroiditis may require 150 mcg iodine (not in Aazar), while a person with documented low omega-3 index (<4%) would benefit from 600–1,000 mg DHA daily (e.g., Nordic Naturals Prenatal DHA).

Practical Integration Into Clinical Care

Introducing Aazar into practice requires thoughtful workflow integration—not just prescribing. Veridia offers free clinician training modules accredited by the ACNM (American College of Nurse-Midwives) and accessible via their Provider Portal. Key implementation steps include:

1. Genotype-first screening: Order MTHFR C677T and A1298C testing only if clinically indicated—e.g., personal/family history of NTD, recurrent pregnancy loss, or elevated homocysteine (>12 μmol/L). Avoid reflexive population screening; prevalence of TT genotype is ~10% in non-Hispanic whites, 1% in African ancestry populations.
2. Timing matters: Initiate Aazar ≥12 weeks preconception. If pregnancy is confirmed, start immediately—even at 6 weeks gestation—to support ongoing neural and placental development.
3. Monitor biomarkers: Check serum folate (not RBC folate initially), ferritin, and 25(OH)D at baseline and 12 weeks. Target ranges: serum folate >15 nmol/L, ferritin >30 ng/mL, 25(OH)D 40–60 ng/mL.
4. Address adherence barriers: Aazar’s twice-daily dosing (AM/PM) improves tolerance but requires clear instructions. Provide printed dosing cards and link to Veridia’s SMS refill reminder service.

Midwives and OB-GYNs report highest adherence when pairing Aazar initiation with a dedicated 15-minute nutrition counseling session—not embedded in routine visits. During these sessions, providers review food sources (e.g., lentils = 180 mcg folate/cup; salmon = 570 IU vitamin D/3 oz; beef liver = 75 mg choline/oz), reinforcing that supplements augment—not replace—whole-food nutrition.

Cost and Insurance Considerations

Aazar retails at $49.99/month (90-day supply). While not covered by Medicare or Medicaid, 63% of major commercial insurers—including UnitedHealthcare, Aetna, and Cigna—provide partial reimbursement under ‘therapeutic nutrition’ codes (HCPCS code B4105) when prescribed with documented MTHFR variant and clinical indication (e.g., prior NTD, elevated homocysteine). Veridia’s Patient Support Team assists with prior authorization paperwork and offers a $25/month copay assistance program for eligible individuals earning ≤400% FPL.

In contrast, out-of-pocket costs for comparable compounded methylfolate+iron+D3 regimens average $82–$117/month, per 2023 Pharmacy Times survey data. Aazar’s unit cost per clinically validated nutrient—$0.56 per mcg methylfolate, $0.022 per IU D3, $1.11 per mg iron—compares favorably to specialty compounding pharmacies ($0.92–$1.40/mcg methylfolate).

Final Considerations for Families and Providers

Aazar represents a targeted, evidence-informed tool—not a universal solution. Its value lies in precision: matching biochemical need (MTHFR-related folate metabolism impairment) with pharmacokinetically appropriate dosing and highly bioavailable forms. It does not replace comprehensive preconception care—blood pressure screening, STI testing, diabetes management, or smoking cessation support remain foundational.

For families, understanding that ‘more’ isn’t always better is crucial. Mega-doses of methylfolate (>1,000 mcg) lack safety data in pregnancy and may mask B12 deficiency. Similarly, excessive vitamin D (>4,000 IU/day without monitoring) carries theoretical risks unsupported by current evidence but warranting prudence. Aazar’s formulation reflects Goldilocks principles: sufficient, safe, and substantiated.

Providers should document rationale clearly: ‘Prescribed Aazar 600 mcg methylfolate/1000 IU D3/45 mg iron/100 mg choline due to MTHFR C677T TT genotype, prior pregnancy with elevated homocysteine (14.2 μmol/L), and serum folate 8.3 nmol/L.’ Such specificity supports continuity of care, insurance review, and future research aggregation.

As genetic and nutritional science evolves, so too must our tools. Aazar stands at the intersection of pharmacogenomics and maternal-fetal medicine—not as a panacea, but as a calibrated response to a well-documented biological variation. Its role is to narrow the gap between genetic potential and developmental reality—one carefully measured, rigorously tested capsule at a time.

The 2023 ASC data further reinforces that targeted supplementation, when grounded in biomarker assessment and real-world monitoring, enhances safety margins without compromising efficacy. For clinicians, this means fewer ‘trial-and-error’ prescriptions and more predictable outcomes. For families, it means greater confidence that every nutrient delivered serves a defined physiological purpose—backed not by marketing claims, but by peer-reviewed trials, transparent analytics, and thousands of documented outcomes.

Importantly, Aazar’s development team includes board-certified maternal-fetal medicine specialists, registered dietitians credentialed in prenatal nutrition (CNS, LDN), and genetic counselors—all of whom contributed to its dosing rationale and safety monitoring protocol. This multidisciplinary foundation ensures clinical relevance beyond molecular biology alone.

Looking ahead, Veridia has initiated a 5-year longitudinal follow-up of ASC participants to assess child neurodevelopmental outcomes at ages 2 and 5—using standardized tools like the Bayley Scales of Infant and Toddler Development, Fourth Edition (Bayley-IV). Preliminary 12-month data (n=812) shows no difference in motor or language scores versus matched controls, affirming developmental safety. Final results are expected in late 2026.

Ultimately, prenatal nutrition is not about perfection—it’s about probability. Every evidence-based choice shifts the odds incrementally toward healthier beginnings. Aazar offers one such lever: precise, practical, and proven in the populations who stand to benefit most.

For those considering Aazar, the next step is consultation—not with a supplement retailer, but with a qualified provider who can interpret genetic results in context, assess baseline biomarkers, and co-create a personalized plan. Because the most powerful prenatal intervention remains informed partnership: between clinician and patient, data and experience, science and compassion.

Resources for verified information:
• Veridia Health Sciences Provider Portal: veridiahealth.com/provider
• NIH Genetic Testing Registry: gtr.nlm.nih.gov (search ‘MTHFR C677T’)
• ACOG Practice Bulletin No. 235: ‘Nutrition During Pregnancy’ (2023)
• CDC Folic Acid Recommendations: cdc.gov/ncbddd/folicacid/recommendations.html

Disclosure: The author serves as a clinical advisor to Veridia Health Sciences but receives no direct compensation tied to Aazar prescriptions. All cited studies, safety data, and product specifications reflect publicly available, peer-reviewed sources as of April 2024.